We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ZYME market cap is 450.85M. The company's latest EPS is USD -1.6925 and P/E is -3.80.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.63M | 402.49M | 35.58M | 7M | 16.51M |
| Operating Income | -50.36M | 319.4M | -27.28M | -54.11M | -33.24M |
| Net Income | -47.85M | 309.43M | -24.35M | -51.15M | -28.69M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 29.54M | 38.95M | 26.68M | 412.48M | 76.3M |
| Operating Income | -150.53M | -187.47M | -215.63M | 130.53M | -137.76M |
| Net Income | -145.44M | -180.55M | -211.84M | 124.34M | -118.67M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 300.26M | 648.73M | 600.74M | 602.05M | 556.37M |
| Total Liabilities | 120.51M | 155.77M | 127.21M | 153.14M | 132.02M |
| Total Equity | 179.76M | 492.96M | 473.54M | 448.92M | 424.34M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 368.21M | 538.38M | 389.13M | 648.73M | 580.88M |
| Total Liabilities | 122.52M | 128.45M | 140.04M | 155.77M | 116.07M |
| Total Equity | 245.68M | 409.92M | 249.09M | 492.96M | 464.81M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -183.25M | 144.11M | -83.19M | -89.59M | -132.26M |
| Investing | -31.78M | -53.85M | -138.22M | -198.9M | -205.92M |
| Financing | 108.96M | 108.58M | 1.74M | 29.34M | 31.24M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -81.85M | -151.4M | -192.45M | 144.11M | -118.3M |
| Investing | -25.59M | -43.44M | 144.6M | -53.85M | -207.25M |
| Financing | 193.66M | 308.98M | 8.01M | 108.58M | 81.85M |
| Market Cap | 450.85M |
| Price to Earnings Ratio | -3.80 |
| Price to Sales Ratio | 5.91 |
| Price to Cash Ratio | 2.86 |
| Price to Book Ratio | 0.97 |
| Dividend Yield | - |
| Shares Outstanding | 70.12M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.4 (5.97%) |
| Company Name | Zymeworks Inc |
| Address |
595 burrard street north vancouver, british columbia V7X 1L3 |
| Website | https://www.zymeworks.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
